Celldex Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Celldex Therapeutics, Inc.
The small-cap biotech is not currently favored by investors but CEO Anat Cohen-Dayag tells Scrip she believes Compugen could have the optimal TIGIT strategy.
Analysts are keen to know more about the statistical weighting of Roche’s SKYSCRAPER 1 study of the TIGIT inhibitor, while Merck & Co can learn from their rival’s slip-up for their own trial design.
After two failures in a row from Roche, the TIGIT hypothesis is looking shaky, but it is too early to write off the class yet.
Pfizer has signed up with a state-owned enterprise for the distribution of its recently approved oral antiviral for COVID-19 in China, where daily case counts are surging amid some tightening restrictions.
- Other Names / Subsidiaries
- Avant Immunotherapeutics, Inc.
- CuraGen Corporation
- Kolltan Pharmaceuticals, Inc.
- Xetrios Therapeutics Inc.